AusCann Group Holdings (ASX:AUC) Files Initial Director's Interest Notice for Andrew Chapman

Aditi Sarkar

02 November 2026 08:52 PM AEDT

AusCann Group Holdings (ASX:AUC) Files Initial Director's Interest Notice for Andrew Chapman

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AusCann Group Holdings (ASX:AUC) has lodged an Appendix 3X Initial Director's Interest Notice with the ASX for director Andrew Chapman.
The notice discloses Chapman's relevant interests in AusCann securities upon appointment to the board, consistent with ASX Listing Rules and the Corporations Act.
AusCann is an Australian medicinal cannabis company engaged in developing and distributing pharmaceutical-grade cannabis products across domestic and international markets.
Director appointment disclosures provide transparency about board members' securities interests, supporting informed assessment of governance alignment.

AusCann Group Holdings Limited (ASX:AUC), the Australian medicinal cannabis company, has submitted an Appendix 3X Initial Director's Interest Notice to the ASX in respect of newly appointed director Andrew Chapman. The notice, filed in accordance with ASX Listing Rule 3.19A.1 and the requirements of the Corporations Act 2001, discloses Chapman's securities interests in AusCann upon commencement of his directorship. The appointment adds to AusCann's board as the company continues to navigate the evolving Australian and international medicinal cannabis regulatory and commercial landscape. The addition of new directors with relevant sector knowledge and commercial experience contributes to the quality of strategic oversight that shareholders rely upon to protect and grow the value of their investment.

Director Interest Disclosure Requirements

An Appendix 3X is a standard ASX regulatory form that all listed entities are required to lodge whenever a new director is appointed to the board. The form requires disclosure of the incoming director's relevant interests in the company's securities at the date of appointment, including any direct or indirect shareholdings, options, performance rights, or other equity-linked instruments. The purpose of this mandatory disclosure is to provide market transparency regarding the financial interests of board members in the companies they govern, allowing investors and other Stakeholders to assess the degree of alignment between director and Shareholder interests. The form becomes part of the ASX's publicly accessible announcement history for the company, ensuring an ongoing record of board-level securities holdings. Chapman's appointment brings additional experience to AusCann's board as the company manages its product development, regulatory approvals, and commercial distribution activities in the medicinal cannabis sector.

AusCann Group Holdings Overview

AusCann Group Holdings is one of Australia's early-listed medicinal cannabis companies, having been among the first to receive the necessary regulatory authorisations to cultivate, produce, and Supply pharmaceutical-grade cannabis products domestically. The company operates under a range of licences from the Australian Office of Drug Control, which oversees the regulated medicinal cannabis sector under the Narcotic Drugs Act 1967. AusCann has focused on developing a portfolio of cannabis-based medicines for conditions including chronic pain, sleep disorders, and other therapeutic indications where clinical evidence for cannabinoid products continues to accumulate. The company distributes medicinal cannabis to registered prescribers and patients through the Therapeutic Goods Administration's Special Access Scheme and the Authorised Prescriber pathway, which collectively govern the majority of medicinal cannabis access in Australia.

Australian Medicinal Cannabis Regulatory Framework

Australia's medicinal cannabis industry operates under a dual-licensing regime administered by both the TGA and the Office of Drug Control. Companies must hold licences for cultivation, production, and manufacture, and products intended for patient use must meet quality and purity specifications set by regulators. The framework has evolved considerably since the sector was formally established in 2016, with the number of licensed participants, product categories, and accessible distribution pathways all expanding substantially. The TGA's approach to medicinal cannabis scheduling and product approval has also matured, with pathways for product registration providing greater market certainty for compliant participants. ASX-listed cannabis companies are subject to both the sector-specific regulatory requirements and the general corporate governance obligations that apply to all publicly listed entities, including the director disclosure requirements that AusCann has fulfilled through this Appendix 3X filing.

Corporate Governance and Board Refreshment

Director appointments and related disclosures are a standard element of corporate governance for ASX-listed companies. Board refreshment brings new skills, perspectives, and networks that can contribute to strategic development, risk oversight, and stakeholder engagement. The Appendix 3X form ensures that any securities interests held by incoming directors are immediately disclosed, maintaining the transparency that market integrity and investor confidence require. AusCann's board has been evolving alongside the company's development, with governance practices adapting as the Business has moved from a pre-revenue explorer to an operating medicinal cannabis company. Changes in director composition are accompanied by a suite of public filings, and the resulting disclosure record provides a transparent account of board-level securities activities for the life of each director's tenure.

Key Insights

The lodgement of an Initial Director's Interest Notice for Andrew Chapman is a routine but important governance event for AusCann Group Holdings. The disclosure reflects the transparency that ASX listing obligations require and provides Market Participants with immediate visibility of the incoming director's securities holdings in the company. For investors tracking AusCann, such disclosures are part of the ongoing information environment that supports well-informed Investment assessment and reflect the company's compliance with its continuous disclosure and governance obligations. The medicinal cannabis sector in Australia continues to evolve, with patient numbers, prescriber engagement, and product diversity all expanding year on year. AusCann, as one of the sector's longer-established participants, carries a historical track record across cultivation, production, and distribution that informs its capacity to grow within the maturing regulatory and commercial environment. Board governance, including transparent disclosure of director interests, remains a foundational element of investor confidence in this developing industry.

FAQs

Q: What is an Appendix 3X Initial Director's Interest Notice?

A: An Appendix 3X is an ASX regulatory disclosure form that a listed company must lodge when a new director is appointed. It sets out the incoming director's relevant interests in the company's securities — including shares, options, and other equity instruments — at the time of their appointment, ensuring market transparency.

Q: Is this announcement price-sensitive?

A: Director interest notices are generally lodged as non-price-sensitive regulatory compliance disclosures. They are mandatory under ASX Listing Rules and the Corporations Act, and their primary purpose is to provide transparency about board composition and interests rather than to communicate market-moving information.

Q: What does AusCann Group Holdings do?

A: AusCann Group Holdings is an ASX-listed Australian medicinal cannabis company that holds licences to cultivate, produce, and supply pharmaceutical-grade cannabis products. It distributes medicinal cannabis to patients through approved TGA regulatory pathways including the Special Access Scheme and the Authorised Prescriber program.

Q: Why is it important to disclose director securities interests?

A: Disclosure of director securities interests is required by ASX Listing Rules and the Corporations Act to ensure market transparency and to allow investors to assess the degree of financial alignment between board members and shareholders. These disclosures also assist in identifying potential conflicts of interest in board decision-making.

Q: What obligations follow the initial director disclosure?

A: After an initial Appendix 3X is lodged, the director must file an Appendix 3Y Change of Director's Interest Notice whenever their relevant interests in the company's securities change — whether through on-market purchases, sales, options or performance rights being granted or exercised, or any other transaction affecting their holdings.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.